Susquehanna International Group, LLP Immuno Gen, Inc. Put Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $417,410 - $1 Million	-33,500 Reduced 6.45%	486,000 $14.4 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $2.29 Million - $3.23 Million	162,800 Added 45.64%	519,500 $8.24 Million
Q2 2023 Aug 11, 2023	SELL	$3.75 - $20.05 $386,625 - $2.07 Million	-103,100 Reduced 22.42%	356,700 $6.73 Million
Q1 2023 May 16, 2023	BUY	$3.67 - $4.92 $673,445 - $902,820	183,500 Added 66.41%	459,800 $1.77 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $903,175 - $1.25 Million	198,500 Added 255.14%	276,300 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $153,216 - $221,274	34,200 Added 78.44%	77,800 $372,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.